Hemodynamics, fluids & transfusion
International pharmacy survey of peripheral vasopressor infusions in critical care (INFUSE)
Authors' conclusion
There is variability in clinical practice regarding PVI administration in critically ill adult patients dependent on drug availability and local institutional recommendations.
Study context
- Population
- Adult ICUs (critical care pharmacists) in Australia, US, UK, Canada and Saudi Arabia
- Participants
- 132 institutions
- Outcome
- Proportion of hospitals administering norepinephrine peripheral vasopressor infusions (PVIs) in critically ill adults
Methodological detailsinternational, multi-centre, survey
- International
- Multi-centre
- Survey
Main finding
As reported in the abstract
Institutions using norepinephrine PVIs
Norepinephrine peripheral vasopressor infusions (PVIs) utilised (n = 113/132)
86%
Observational data: associations, not effects.
Secondary outcomes
Maximum duration of norepinephrine PVIs
- Median maximum duration, IQR 24-24 (n = 57/113)
- 24 h
Maximum norepinephrine PVI rate
- Most common maximum rate (n = 16/113)
- between 11 and 20 μg/min
Maximum norepinephrine PVI concentration
- Most common maximum concentration (n = 60/113)
- 16 μg/mL
Preference for another PVI over norepinephrine as first-line
- Half of institutions (n = 66/132)
Most common alternative PVI by country
- US: phenylephrine (n = 37/90)
- 41%
- Canada: dopamine (n = 5/16)
- 31%
- UK: metaraminol (n = 9/11)
- 82%
- Australia: metaraminol (n = 8/9)
- 89%
Original publication
International pharmacy survey of peripheral vasopressor infusions in critical care (INFUSE). J Crit Care. Published 2 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →